Nicardipine calcium channel blockers

Description Results NMA

nicardipine (n=-9)

vs.

(n=-9)

Double blind

Sample size: -9/-9

Primary endpoint:

FU duration: 4 months

nicardipine (n=-9)

vs.

(n=-9)

Double blind

Sample size: -9/-9

Primary endpoint:

FU duration: 4 months

all cause death 1.00 [0.14; 7.00]

coronary heart disease 1.00 [0.14; 7.00]

cardiovascular death ∞ [NaN; ∞]

fatal MI NaN [NaN; NaN]

heart failure 0.00 [0.00; NaN]

fatal stroke ∞ [NaN; ∞]

non fatal stroke 1.03 [0.39; 2.69]

non fatal MI 1.03 [0.15; 7.24]

stroke (fatal & non fatal) 0.75 [0.26; 2.12]

Major cardiovascular events 0.69 [0.30; 1.58]

Nicardipine SR 20mg twice daily (n=215)

vs.

trichlormethiazide 2mg once daily (n=214)

Double blind

Parallel groups

Sample size: 215/214

Primary endpoint: CV events

FU duration: 4.5 years